Strong Buy · 83/100Jul 30, 3:05 PM EDT
Alnylam Projects $4.7B-$5.1B 2026 Product Revenue, Eyes 25% TTR CAGR to 2030
ALNY
Alnylam Pharmaceuticals (ALNY) reported strong Q2 2026 results, with AMVUTTRA quarterly revenues surpassing $1 billion for the first time. The company forecasts $4.7B-$5.1B in 2026 product revenue and targets a 25% TTR revenue CAGR through 2030, signaling robu…
- ▹Strong commercial growth with AMVUTTRA surpassing $1B quarterly run rate, supported by robust TTR franchise and pipeline.
- ▹Platform-based RNAi technology with multiple assets and recent approvals, though no specific regulatory catalysts in this news.
Strong Buy · 83/100Jul 30, 2:27 PM EDT
Regeneron Projects Mid-Teens Growth for EYLEA HD as Prefilled Syringe Rollout Gains Traction
REGN
Regeneron (REGN) expects EYLEA HD demand to grow in the low-to-mid teens during Q3–Q4 2026, driven by the ongoing prefilled syringe launch. The company reported strong Q2 2026 results with total revenues up 17% and non-GAAP EPS up 11%, while key products like…
- ▹EYLEA HD is a commercialized product with strong demand growth and no regulatory issues, supported by a prefilled syringe push.
- ▹Regeneron is a platform company with multiple marketed assets (Dupixent, Libtayo) and robust revenue growth.
Strong Buy · 80/100Jul 31, 12:05 PM EDT
Moderna Maintains 2026 Revenue Growth Outlook, Trims Cash Burn Guidance to $4B
MRNA
Moderna (MRNA) reiterated its guidance for up to 10% revenue growth in 2026 while lowering its cash cost guidance to approximately $4 billion. The company reported Q2 revenue of $0.1 billion, exceeding expectations, and a net loss of $0.8 billion, ending the q…
- ▹Strong cash position and reiterated growth guidance signal financial stability.
- ▹Platform technology with multiple mRNA assets and recent FDA approvals support long-term value.
Watchlist · 67/100Jul 31, 12:23 AM EDT
Veracyte Projects $590M-$596M in 2026 Revenue, Accelerates Prosigna and TrueMRD Rollouts
VCYT
Veracyte (VCYT) provided 2026 revenue guidance of $590M-$596M, reflecting strong growth driven by the launch of Prosigna LDT and TrueMRD. The company's Q2 marked a milestone with these product launches, expanding its portfolio and positioning for significant r…
- ▹Prosigna and TrueMRD launches expand portfolio with differentiated diagnostics, but single-asset focus and no major regulatory catalysts cap upside.
- ▹Strong revenue guidance ($590M-$596M) indicates commercial traction, but trial-stage pipeline and lack of manufacturing details limit score.
Watchlist · 67/100Jul 30, 9:15 PM EDT
CareDx Boosts 2026 Revenue Forecast to $490M-$500M on NavDx Rollout
CDNA
CareDx (CDNA) raised its 2026 revenue guidance to $490M-$500M, driven by the integration of its NavDx product. Management noted the completion of its portfolio shift toward specialty oncology and cell therapy, signaling growth potential for investors.
- ▹Raised 2026 revenue outlook to $490M-$500M, indicating strong commercial growth and demand for NavDx.
- ▹Portfolio shift into specialty oncology and cell therapy, but single-asset focus and no recent FDA catalysts cap upside.
Watchlist · 65/100Jul 31, 11:54 AM EDT
Oppenheimer Starts Bicycle Therapeutics at Outperform, Citing Differentiated Cancer Platform
BCYC
Oppenheimer initiated coverage on Bicycle Therapeutics (BCYC) with an Outperform rating, highlighting its platform's unique combination of biologic and small molecule advantages for oncology. The analyst believes this differentiated approach offers broad thera…
- ▹Differentiated platform combining biologics and small molecules, with broad oncology potential.
- ▹Positive analyst initiation, but early-stage pipeline and single-asset risk cap upside.
Watchlist · 65/100Jul 30, 8:44 PM EDT
Neurocrine Lifts 2026 INGREZZA Sales Outlook to $2.825B-$2.875B as VYKAT XR Integration Advances
NBIX
Neurocrine Biosciences (NBIX) raised its 2026 INGREZZA sales guidance to $2.825B-$2.875B after a record Q2 with net product sales exceeding $950M, driven by its portfolio including INGREZZA, CRENESSITY, and VYKAT XR. Management plans disciplined capital deploy…
- ▹INGREZZA sales guidance raised, indicating strong commercial demand and growth.
- ▹Integration of VYKAT XR adds pipeline depth, but single-asset dependence and dilution risk from acquisition temper upside.
Neutral · 62/100Jul 30, 1:54 PM EDT
Agios Guides 2026 Pyruvate Kinase Deficiency Sales to $45M-$50M Ahead of Key Sickle Cell FDA Decision
AGIO
Agios Pharmaceuticals reported Q2 net revenue of $44.7 million, including $40.9 million from its PK deficiency drug, and guided 2026 PK deficiency revenue to $45M-$50M. The company is preparing for a November 1 PDUFA date for its sickle cell disease candidate,…
- ▹Upcoming PDUFA for sickle cell disease adds regulatory upside, but single-asset focus and dilution risk temper enthusiasm.
- ▹Strong commercial execution in PK deficiency provides revenue base, but pipeline is early-stage and lacks platform breadth.
Neutral · 60/100Jul 31, 11:33 AM EDT
Replimune Surges as FDA Panel Backs Melanoma Therapy; Cantor Lifts Rating
REPL
Replimune (REPL) shares rebounded after an FDA advisory committee voted in favor of its lead candidate RP1 for melanoma, prompting Cantor Fitzgerald to upgrade the stock. The positive vote boosts the likelihood of regulatory approval, a key catalyst for the bi…
- ▹Positive AdCom vote for RP1 in melanoma supports regulatory path, but FDA decision pending.
- ▹Single-asset platform with limited commercial data; manufacturing unknown.
Neutral · 60/100Jul 30, 5:01 PM EDT
Amgen Maintains Quarterly Payout with $2.52 Dividend
AMGN
Amgen (AMGN) declared a quarterly dividend of $2.52 per share, consistent with its previous payout, resulting in a forward yield of 2.6%. The dividend is payable on September 11 to shareholders of record as of August 21, with the ex-dividend date also on Augus…
- ▹Dividend declaration is routine, no impact on pipeline or regulatory outlook.
- ▹Amgen has a broad portfolio and manufacturing capabilities, but this news is not a catalyst.
Neutral · 59/100Jul 31, 1:34 AM EDT
Myriad Genetics Projects 2026 Revenue of $770M-$790M, Withdraws EBITDA Guidance
MYGN
Myriad Genetics (MYGN) reported Q2 2026 revenue of $190.7 million, down 11% year-over-year, and provided 2026 revenue guidance of $770M-$790M with gross margins of 66%-67%. The company suspended its adjusted EBITDA guidance, citing uncertainty. Investors shoul…
- ▹Revenue decline and suspended EBITDA guidance raise concerns, but established commercial portfolio and no regulatory negatives provide some stability.
- ▹Single-asset focus and lack of platform differentiation cap upside, while manufacturing is not a key strength.
Neutral · 58/100Jul 30, 11:00 PM EDT
Replimune Soars After FDA Panel Backs RP1
REPLBMY
Replimune's stock more than doubled in after-hours trading following a favorable FDA advisory committee vote on its lead drug RP1. The positive recommendation boosts the likelihood of approval ahead of the August 2 PDUFA date, a key catalyst for REPL investors…
- ▹Positive AdCom vote for RP1, but FDA decision pending; single-asset company with limited pipeline diversity.
- ▹Platform potential (oncolytic immunotherapy) but early-stage commercial profile and no manufacturing details.
High Risk · 37/100Jul 31, 2:09 PM EDT
Novo's Trial Failure Sinks Monte Rosa and BioAge Shares
BIOANVONBIXNMRA
Monte Rosa Therapeutics (GLUE) and BioAge Labs (BIOA) saw their stocks plunge after Novo Nordisk's (NVO) late-stage trial setback raised doubts about the mechanisms of their experimental heart disease drugs. The news highlights the risks in the biotech sector…
- ▹Novo's trial setback casts doubt on mechanism, impacting related assets.
- ▹Pipeline uncertainty and negative sentiment drive high risk.
High Risk · 27/100Jul 30, 7:38 PM EDT
Karyopharm shares crater after Xpovio misses endpoint in endometrial cancer study
KPTI
Karyopharm Therapeutics (KPTI) announced that Xpovio (selinexor) failed to meet its primary endpoint of progression-free survival in a phase 3 trial for TP53 wild-type advanced endometrial cancer. The stock plunged about 69% in after-hours trading, reflecting…
- ▹Phase 3 failure in endometrial cancer, no PFS benefit, severe negative regulatory and commercial impact.
- ▹Single-asset risk with no near-term catalysts, likely dilution risk and runway concerns.